AZ/Daiichi Sankyo’s Enhertu gets second US cancer indicationAstraZeneca and Daiichi Sankyo’s Enhertu cancer drug has picked up a second indication, in patients who have stomach Share XAZ/Daiichi Sankyo’s Enhertu gets second US cancer indicationhttps://pharmaphorum.com/news/az-daiichi-sankyos-enhertu-gets-second-us-cancer-indication/
MacroGenics’ HER2 breast cancer drug Margenza approved in USMacroGenics’ HER2-targeted breast cancer drug Margenza has been approved by the FDA, challenging several recently approved drugs with Share XMacroGenics’ HER2 breast cancer drug Margenza approved in UShttps://pharmaphorum.com/news/macrogenics-her2-breast-cancer-drug-margenza-approved-in-us/
Daiichi Sankyo, AZ close on EU approval of Enhertu for breast cancerDaiichi Sankyo and AstraZeneca could be just weeks away from an EU approval for their antibody-drug conjugate (ADC) Share XDaiichi Sankyo, AZ close on EU approval of Enhertu for breast cancerhttps://pharmaphorum.com/news/daiichi-sankyo-az-close-on-eu-approval-of-enhertu-for-breast-cancer/
Scotland says no to Daiichi Sankyo’s cholesterol drug NilemdoThe Scottish Medicines Consortium (SMC) has rejected Daiichi Sankyo’s new cholesterol-lowering drug Nilemdo for use by NHS Scotland, Share XScotland says no to Daiichi Sankyo’s cholesterol drug Nilemdohttps://pharmaphorum.com/news/scotland-says-no-to-daiichi-sankyos-cholesterol-drug-nilemdo/
Gilead pays $21bn for Immunomedics ahead of breast cancer trial readoutGilead has made another big oncology acquisition, paying $21 billion for US biotech Immunomedics and its potential cancer Share XGilead pays $21bn for Immunomedics ahead of breast cancer trial readouthttps://pharmaphorum.com/news/gilead-pays-21bn-for-immunomedics-ahead-of-breast-cancer-trial-readout/
AstraZeneca inks $6bn cancer drug deal with Daiichi SankyoAstraZeneca has begun a new agreement with Daiichi Sankyo to develop and market an antibody to treat cancer, Share XAstraZeneca inks $6bn cancer drug deal with Daiichi Sankyohttps://pharmaphorum.com/news/astrazeneca-inks-6bn-cancer-drug-deal-with-daiichi-sankyo/
After Celgene deal, BMS shoots up pharma market cap rankingsBristol-Myers Squibb $74 billion takeover of Celgene saw it shoot up the list of top 20 pharma companies Share XAfter Celgene deal, BMS shoots up pharma market cap rankingshttps://pharmaphorum.com/news/after-celgene-deal-bms-shoots-up-pharma-market-cap-rankings/
ASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cancersWith an FDA approval for HER2-positive breast cancer already in the bag, Daiichi Sankyo and AstraZeneca’s Enhertu now Share XASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cancershttps://pharmaphorum.com/news/asco-2020-astrazeneca-enhertu-cancer/
AZ/Daiichi’s Enhertu gains second ‘breakthrough’ tag in space of a weekThe FDA has said AstraZeneca and Daiichi Sankyo’s Enhertu could be a breakthrough in a potential new lung cancer niche, the second time in the Share XAZ/Daiichi’s Enhertu gains second ‘breakthrough’ tag in space of a weekhttps://pharmaphorum.com/news/azs-enhertu-gains-second-breakthrough-tag-in-space-of-a-week/
